Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF

Last updated: July 31, 2025
Sponsor: Henan University of Traditional Chinese Medicine
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Cystic Fibrosis

Lung Disease

Lung Injury

Treatment

Jin-shui Huan-xian granule

Jin-shui Huan-xian granule placebo

Clinical Study ID

NCT06914713
CM for IPF
  • Ages 40-85
  • All Genders

Study Summary

This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui Huan-xian Formula for retarding the decline of pulmonary function in Idiopathic Pulmonary Fibrosis（IPF）

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients who meet the diagnostic criteria for IPF.

  2. Pulmonary function: The percentage of forced vital capacity (FVC) to the predictedvalue is ≥ 50%; and the percentage of the diffusing capacity of the lung for carbonmonoxide (DLCO) to the predicted value is ≥ 30%.

  3. Patients who meet the syndrome - differentiation criteria for lung - qi deficiencysyndrome, lung - and - kidney qi deficiency syndrome, etc.

  4. Aged between 40 and 85 years old.

  5. Patients who voluntarily accept the treatment and sign the informed consent

Exclusion

Exclusion Criteria:

  1. Patients in the acute exacerbation phase of IPF.

  2. Patients complicated with other pulmonary diseases such as chronic obstructivepulmonary disease (COPD), lung cancer, active pulmonary tuberculosis,bronchiectasis, and pulmonary embolism.

  3. Patients with severe joint, peripheral nerve, and peripheral vascular diseases thataffect limb movement and who are bed - ridden for a long time and cannot completethe six - minute walk test.

  4. Patients complicated with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, heartfunction grade 3 or above, stroke, cerebral hemorrhage, etc.).

  5. Patients complicated with liver diseases such as cirrhosis or secondary portalhypertension, bleeding caused by esophageal and gastric varices, patients withkidney diseases requiring dialysis or kidney transplantation, or patients withabnormal liver and kidney functions (ALT, AST, and BUN are 1.5 times higher than theupper limit of the normal range, and blood Cr is higher than the upper limit of thenormal range).

  6. Patients with unclear consciousness, various mental illnesses, etc., who cannotcommunicate normally.

  7. Pregnant or lactating women and patients with a recent plan for pregnancy.

  8. Patients who have participated in other clinical trials within 1 month beforeenrollment.

  9. Patients known to be allergic to any of the test medications and their components.

Study Design

Total Participants: 384
Treatment Group(s): 2
Primary Treatment: Jin-shui Huan-xian granule
Phase:
Study Start date:
August 01, 2025
Estimated Completion Date:
November 30, 2028

Study Description

The study took 384 IPF patients as the research objects and adopted a randomized, double

  • blind, placebo - controlled trial design. The patients were randomly divided into an experimental group and a control group. On the basis of guideline - guided treatment, the experimental group was given Jin-shui Huan-xian Formula, and the control group was given a placebo of Jin-shui Huan-xian Formula. The treatment lasted for 52 weeks. Pulmonary function (FVC) was set as the primary outcome indicator, and acute exacerbation, pulmonary function (DLCO, DLCO%, etc.), exercise endurance, quality of life, etc. were set as secondary outcome indicators. Blood routine, urine routine, liver function, renal function, electrocardiogram, etc. were set as safety indicators. The clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF were evaluated to generate high - quality clinical evidence and establish a treatment plan of Jin-shui Huan-xian Formula for retarding the decline of pulmonary function in IPF.

Connect with a study center

  • the First Affiliated Hospital of Henan University of Chinese Medicine

    Zhengzhou, Henan 450056
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.